Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging

AbstractPurposeWe investigated the changes of tissue oxygen saturation (sO2) in sorafenib-treated HCC (hepatocelluar carcinoma) mouse models using photoacoustic imaging (PI).Materials and MethodsNude mice, implanted with human HCC (HepG2-RFP) cells in the liver, were randomised to the sorafenib-treated group (n = 21) or the control group (n = 20). Tumour volume and sO2 were measured by PI at baseline and then one week later, and radiant efficiency (RE) and therapeutic response were analysed by fluorescence imaging and histologic analysis.ResultsSorafenib was effective in treating HCC by evaluating necrotic fraction, apoptosis index, and microvessel density (MVD). One week after treatment, the sO2 of HCC and residual healthy liver tissue decreased, and the hypoxia inducible factor-1α (HIF-1α) protein expression of HCC increased, correlating with the apoptosis index. The ΔsO2 in HCC showed a significantly positive correlation with the necrotic fraction and the apoptosis index of tumour and a negative correlation with the MVD of tumour.ConclusionSorafenib treatment results in changes of sO2 in HCC and liver parenchyma and induces the accumulation of HIF-1α by hypoxic environment. sO2 as measured by PI, can be a useful marker for non-invasive monitoring of the therapeutic response in orthotopic HCC mouse models.Key Points• Hypoxia is a characteristic feature of the tumour microenvironment • It is important to monitor sO2in HCC during sorafenib treatment • PI is useful for non-invasive monitoring of sO2in HCC.• ΔsO2in HCC showed a significantly correlation with tumour response.

[1]  Tayyaba Hasan,et al.  Prediction of Tumor Recurrence and Therapy Monitoring Using Ultrasound-Guided Photoacoustic Imaging , 2015, Theranostics.

[2]  S. Påhlman,et al.  Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.

[3]  N. Tamaki,et al.  Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT , 2014, BMC Cancer.

[4]  Jianxiang Wang,et al.  Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. , 2014, Biomaterials.

[5]  A. Harris,et al.  Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality , 2015, EMBO molecular medicine.

[6]  Jan Laufer,et al.  Quantitative spatially resolved measurement of tissue chromophore concentrations using photoacoustic spectroscopy: application to the measurement of blood oxygenation and haemoglobin concentration , 2007, Physics in medicine and biology.

[7]  Jun Wang,et al.  Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[8]  H. Moon,et al.  Hypoxia-induced angiogenesis in human hepatocellular carcinoma , 2002, Journal of Molecular Medicine.

[9]  M. Welker,et al.  Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. , 2011, World journal of gastroenterology.

[10]  Moustapha Hassan,et al.  Real-Time Assessment of Tissue Hypoxia In Vivo with Combined Photoacoustics and High-Frequency Ultrasound , 2014, Theranostics.

[11]  B. Kholodenko,et al.  Evaluating Strategies to Normalise Biological Replicates of Western Blot Data , 2014, PloS one.

[12]  Wenxin Qin,et al.  Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma , 2015, Oncogene.

[13]  N. Weidner Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.

[14]  Liang Zhao,et al.  MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1α , 2014, PloS one.

[15]  N. Tamaki,et al.  Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma , 2012, International journal of oncology.

[16]  R. Wenger,et al.  The hypoxia-inducible factor-1α is a negative factor for tumor therapy , 2003, Oncogene.

[17]  Baorui Liu,et al.  Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo , 2015, Nature Communications.

[18]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.

[19]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[20]  H. Eguchi,et al.  Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection , 2012, Annals of Surgical Oncology.

[21]  B. Krock,et al.  Hypoxia-induced angiogenesis: good and evil. , 2011, Genes & cancer.

[22]  R. Jain,et al.  Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal‐derived factor 1 alpha/C‐X‐C receptor type 4 axis and myeloid differentiation antigen–positive myeloid cell infiltration in mice , 2014, Hepatology.

[23]  A. le Pape,et al.  High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology , 2016, PloS one.

[24]  A. Mousa,et al.  Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma , 2008, Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association.

[25]  G. Semenza Hypoxia and cancer , 2007, Cancer and Metastasis Reviews.

[26]  Wei Zheng,et al.  Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound. , 2010, Academic radiology.

[27]  V. Goh,et al.  Molecular imaging of hypoxia in non-small-cell lung cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  L. Rich,et al.  Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level-dependent MR imaging. , 2015, Radiology.

[29]  Y. Imai,et al.  Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[30]  G. Chen,et al.  Sorafenib Inhibits Hypoxia-Inducible Factor-1α Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma , 2012, Clinical Cancer Research.

[31]  A. Needles,et al.  Development and initial application of a fully integrated photoacoustic micro-ultrasound system , 2013, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.

[32]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[33]  P. Beard Biomedical photoacoustic imaging , 2011, Interface Focus.

[34]  Zhao-You Tang,et al.  Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives , 2004, Journal of Cancer Research and Clinical Oncology.

[35]  Xuehua Xu,et al.  Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer. , 2015, International journal of clinical and experimental medicine.

[36]  Y. Urano,et al.  Photoacoustic Tomography of Human Hepatic Malignancies Using Intraoperative Indocyanine Green Fluorescence Imaging , 2014, PloS one.

[37]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models , 2007, Cancer Chemotherapy and Pharmacology.

[38]  J. Miyazaki,et al.  Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. , 2001, Cancer research.

[39]  Ying-jian Liang,et al.  Hypoxia‐mediated sorafenib resistance can be overcome by EF24 through Von Hippel‐Lindau tumor suppressor‐dependent HIF‐1α inhibition in hepatocellular carcinoma , 2013, Hepatology.

[40]  山下 洋市 Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model , 2002 .

[41]  R. Wenger,et al.  The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. , 2003, Oncogene.

[42]  B. Zhai,et al.  Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. , 2013, World journal of hepatology.

[43]  R. Coffey,et al.  Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[44]  M. Yoshimura,et al.  Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels , 2012, Nature Communications.

[45]  A. Taketomi Clinical trials of antiangiogenic therapy for hepatocellular carcinoma , 2016, International Journal of Clinical Oncology.

[46]  M. Mejías,et al.  Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.